Cohort B of the Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter

Exclusion Criteria

• •Patient unable to give informed consent.
• •Elevated CK-MB or troponin at baseline
• •Patient is known or suspected not to tolerate the contrast agent
• •Chronic Total Occlusion is located in aorto-ostial location, SVG CTO, in-stent occlusion
• •Appearance of a fresh thrombus or intraluminal filling defects
• •Intolerance to Aspirin and/or inability to tolerate a second antiplatelet agent (Clopidogrel and Prasugrel and Ticagrelor)
• •Cardiac intervention within 4 weeks of the procedure
• •Severe renal insufficiency with eGFR\<30 ml/min/1.72 m2
• •Congestive heart failure \[New York Heart Association (NYHA) Class III\\IV\] CSA Class IV
• •Life expectancy \< 2 years due to other illnesses
• •Acute or unstable medical disorder/disease that may cause a risk to patient, including:
• •i. Recent myocardial infarction (MI) (within the past two weeks) ii. Significant anemia (e.g. hemoglobin \< 8.0 mg / dl) iii. Recent major cerebrovascular event (history of stroke or TIA within 1 month) iv. Severe uncontrolled systemic hypertension (e.g., \>180/100 mmHg) v. Unstable angina requiring emergent percutaneous trans-luminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG)